scholarly journals PBI29 LITERATURE REVIEW ON TOTAL MEDICAL COSTS AND COST COMPONENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPIES

2019 ◽  
Vol 22 ◽  
pp. S422
Author(s):  
Q. Ma ◽  
D. Kuzan ◽  
J. Zhang
Keyword(s):  
T Cell ◽  
Literature Review ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Medical Costs ◽  
Car T ◽  
Cost Components

scholarly journals CAR-T-ICI: Kombinasi chimeric antigen receptor T-cell dengan immune checkpoint inhibitor anti PD-1 selaku pilihan terapi terbaru kanker kolorektal

2021 ◽  
Vol 9 (1) ◽  
pp. 56-68
Author(s):  
Imam Hermansyah ◽  
Eddy Zulfikar
Keyword(s):  
T Cell ◽  
Literature Review ◽  
Chimeric Antigen Receptor ◽  
Objective Response ◽  
Antigen Receptor ◽  
Car T Cell ◽  
Programmed Cell Death 1 ◽  
Tnf Α ◽  
Car T ◽  
Ifn Γ

ABSTRAK Pendahuluan: Kanker kolorektal selaku keganasan ketiga tersering di dunia umumnya ditangani dengan operasi, radioterapi, maupun kemoterapi berdasarkan stadium penyakitnya. Namun, akibat prosedur invasif dan efek samping yang ditimbulkan oleh terapi tersebut, Chimeric Antigen Receptor (CAR) T-cell hadir sebagai pilihan terapi terbaru yang bersifat lebih spesifik terhadap sel tumor. Efektivitas CAR T-cell untuk mengobati tumor padat masih terbatas oleh karena molekul imun inhibitorik, Programmed Cell Death-1 (PD-1) yang memiliki efek imunosupresif terhadap sel T. Oleh karena itu, penyusunan literature review ini bertujuan untuk mengkaji potensi terapi kombinasi imunoterapi CAR-T cell dengan anti PD-1 dalam pengobatan kanker kolorektal stadium lanjut. Metode: Literature review ini disusun menggunakan metode studi pustaka dengan strategi pencarian jurnal ilmiah PubMed yang kemudian dianalisis secara sistematis.  Pembahasan: Berdasarkan studi sebelumnya, ekspresi EpCAM dalam jumlah tinggi ditemukan pada sel kanker kolorektal.  Sekresi IFN-γ dan TNF-α dalam jumlah yang tinggi ditemukan pada sel tumor EpCAM positif menunjukkan bahwa EpCAM-CAR-T cell memiliki efek sitotoksik spesifik terhadap sel tumor target. Rata-rata volume tumor kolorektal pada kelompok EpCAM CAR-T cell lebih rendah dibanding kontrol, menunjukkan EpCAM-CAR-T cell mampu menghambat pembentukan dan pertumbuhan sel tumor. Di sisi lain, 35,8% pasien kanker kolorektal metastasis diketahui memiliki objective response rate dan 73,6% diantaranya tercatat memiliki disease control rate ≥12 minggu setelah terapi anti PD-1 nivolumab, menunjukkan efektivitas nivolumab dalam pengendalian penyakit jangka panjang dengan masa survival yang lebih lama pada pasien kanker kolorektal metastasis. Simpulan: Kombinasi imunoterapi EpCAM CAR-T cell dengan anti PD-1 memiliki potensi sebagai pengobatan terbaru yang efektif untuk kanker kolorektal stadium lanjut.   Kata kunci: Anti PD-1, CAR-T cell, imunoterapi, kanker kolorektal

Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies

Immunotherapy ◽  
2020 ◽  
Vol 12 (18) ◽  
pp. 1341-1357
Author(s):  
Nashwa El-Khazragy ◽  
Sherief Ghozy ◽  
Passant Emad ◽  
Mariam Mourad ◽  
Diaaeldeen Razza ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Chimeric Antigen Receptor ◽  
Hematological Malignancies ◽  
Antigen Receptor ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
Challenges And Opportunities

Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory hematological malignancies. Despite the great results of the CAR-T-cell therapy, many tumors are still able to avoid immune detection and further elimination, as well as the possible associated adverse events. Herein, we highlighted the recent advances in CAR-T-cell therapy, discussing their applications beneficial functions and side effects in hematological malignancies, illustrating the underlying challenges and opportunities. Furthermore, we provide an overview to overcome different obstacles using potential manufacture and treatment strategies.

scholarly journals Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects

2020 ◽  
Author(s):  
Javad Masoumi ◽  
Abdollah Jafarzadeh ◽  
Jalal Abdolalizadeh ◽  
Haroon Khan ◽  
Jeandet Philippe ◽  
...  
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
Cell Therapy ◽  
Cancer Stem Cell ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T

scholarly journals Invasive Fungal Infections after Anti-CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy: State of the Evidence and Future Directions

2021 ◽  
Vol 7 (2) ◽  
pp. 156
Author(s):  
Will Garner ◽  
Palash Samanta ◽  
Ghady Haidar
Keyword(s):  
Risk Factors ◽  
T Cell ◽  
Cell Therapy ◽  
Chimeric Antigen Receptor ◽  
Fungal Infections ◽  
Antigen Receptor ◽  
Invasive Fungal Infections ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T

Studies describing invasive fungal infections (IFIs) after chimeric antigen receptor-modified T-cell (CAR-T-cell) therapy are limited. Although post-CAR-T-cell IFIs appear to be uncommon, they are associated with significant morbidity and mortality. Specific risk factors for IFIs in CAR-T-cell recipients have not been fully characterized and are often extrapolated from variables contributing to IFIs in patients with other hematologic malignancies or those undergoing hematopoietic cell transplant. Optimal prophylaxis strategies, including the use of yeast versus mold-active azoles, also remain ill-defined. Further research should investigate key risk factors for IFIs and establish an evidence-based approach to antifungal prophylaxis in these patients in order to improve clinical outcomes.

scholarly journals Continuous Telemetry Monitoring in Chimeric Antigen Receptor (CAR) T-Cell Therapy Patients

2021 ◽  
Vol 27 (3) ◽  
pp. S211-S212
Author(s):  
Eddie Stephens ◽  
Ansh Mehta ◽  
Tanya Persoon ◽  
Shannon Baker ◽  
Remy David ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T

scholarly journals HGG-05. REGRESSION OF RECURRENT GLIOBLASTOMA AFTER BORON NEUTRON CAPTURE THERAPY AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN A CHILD

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii345-iii345
Author(s):  
Hsin-Hung Chen ◽  
Yi-Wei Chen
Keyword(s):  
T Cells ◽  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Antigen Receptor ◽  
Neutron Capture Therapy ◽  
T Cell Therapy ◽  
Boron Neutron Capture ◽  
Car T

Abstract A 6 y/o girl with recurrent multifocal glioblastoma received 3 times of boron neutron capture therapy (BNCT) and chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen HER2. Multiple infusions of CAR T cells were administered over 30 days through intraventricular delivery routes. It was not associated with any toxic effects of grade 3 or higher. After BNCT and CAR T-cell treatment, regression of all existing intracranial lesions were observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, but new lesions recurred soon after the treatment. This clinical response continued for 14 months after the initiation of first recurrence.

OP206 Expert Elicitation Of Probabilistic Distributions to Inform Survival Modelling of CD19 Chimeric Antigen Receptor T-Cell Therapies

2020 ◽  
Vol 36 (S1) ◽  
pp. 3-3
Author(s):  
Niamh Carey ◽  
Conor Hickey ◽  
Laura Mc Cullagh ◽  
Michael Barry
Keyword(s):  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Expert Elicitation ◽  
Cell Transplant ◽  
Major Advance ◽  
Cell Therapies ◽  
Risk Of Death ◽  
Car T Cell ◽  
Car T

IntroductionIn 2018, the National Centre for Pharmacoeconomics (NCPE) was commissioned to conduct a health technology assessment (HTA) of one of the first commercially available chimeric antigen receptor (CAR) T-cell therapies, tisagenlecleucel. CAR T-cells are a major advance in personalized cancer treatment, demonstrating promising outcomes in relapsed/refractory pediatric acute lymphoblastic leukemia (pALL). However, the results are based on short-term follow up, limiting their value in predicting long-term survival and leading to uncertainty about the most appropriate survival modeling method to employ. This study aimed to address these limitations by means of expert elicitation.MethodsAn expert elicitation method, the histogram technique, was employed. A predefined discrete numerical scale was presented in Microsoft Excel® and the expert was asked to place twenty crosses on a frequency chart. These crosses represented the expert's beliefs about the distribution of particular quantities. Each cross represented five percent of the probabilistic distribution. Individual distributions were then aggregated across experts using linear pooling.ResultsA total of seventeen experts were invited to take part; eight agreed to participate and five completed the exercise. Three experts did not consider tisagenlecleucel to be a “curative” therapy because patients had a higher risk of death, compared with the age- and sex-matched general population. The aggregated distributions indicated the five-year overall survival rate to be thirty-three percent (95% CI 8.65–56.88) in patients who do not receive a subsequent stem cell transplant and twenty percent (95% CI 2.38 -52.04) in those who do.ConclusionsThe results of this study will be used to calibrate CD19 CAR T-cell therapy survival estimates presented in HTA submissions to the NCPE to ensure more robust assessments. They will also be used to inform the construction of a de novo cost-utility model for examining the cost effectiveness of CD19 CAR T-cell therapies for relapsed/refractory pALL in the Irish healthcare setting.

scholarly journals Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice

2021 ◽  
Author(s):  
Giulia Bonaldo ◽  
Nicola Montanaro ◽  
AlbertoVaccheri ◽  
Domenico Motola
Keyword(s):  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Clinical Setting ◽  
Safety Profile ◽  
Antigen Receptor ◽  
The United States ◽  
Reporting Odds Ratio ◽  
Cytokine Release ◽  
Car T ◽  
Age Range

Abstract Purpose Two chimeric antigen receptor T-cell (CAR-T) therapies have been approved in the United States (USA) in 2017 and Europe (EU) in 2018: axicabtagene ciloleucel and tisagenlecleucel. They contain the patient’s own T cells, which are extracted, genetically modified, and reinfused. Alongside the good efficacy results, the assessment of safety profile of these new therapies represents a great challenge. Our aim was to analyze the reports of the adverse drug reactions (ADR) after CAR-T administration as occurred in the real clinical setting. Methods We performed a retrospective observational study, collecting all the reports in EU (EudraVigilance, EV) and US (FAERS) databases of ADRs regarding axicabtagene ciloleucel and tisagenlecleucel. Both descriptive and statistical analyses were performed, the latter by using Reporting Odds Ratio (ROR). Results A total number of 1426 reports of suspected ADRs were retrieved in EudraVigilance and FAERS. Patients’ reported age reflected the age range for which the drugs are approved (18–64 years for axicabtagene ciloleucel and patients aged under 25 years for tisagenlecleucel). The most reported event was cytokine release syndrome (CRS), 185 events for tisagenlecleucel and 462 for axicabtagene ciloleucel in FAERS and 137 and 498, respectively, in EudraVigilance. A disproportionality was found comparing axicabtagene ciloleucel with tisagenlecleucel for the above-mentioned event: EV ROR 2.47, 95% CI 2.22–2.74, FAERS 1.89, 1.70–2.10. Conclusion CRS represents the major problem with the administration of CAR-T therapies. Our analysis has not revealed new ADRs; however, it supports the safety profile of CAR-T with new data from real clinical setting.

Sign in / Sign up

Export Citation Format

Share Document